DIAGNOSIS OF MYELOMA BASED ON THE 2014 INTERNATIONAL MYELOMA WORKING GROUP

Authors

  • Maitri Febrianthi Department of Clinical Pathology, Faculty of Medicine, Universiy of Indonesia, Jakarta, Indonesia. E-mail:
  • Riadi Wirawan Department of Clinical Pathology, Faculty of Medicine, Universiy of Indonesia, Jakarta, Indonesia. E-mail:

DOI:

https://doi.org/10.24293/ijcpml.v24i2.1324

Keywords:

Myeloma, update diagnosis myeloma, free light chain serum, myeloma defining events

Abstract

Myeloma is a cytogenetically heterogenous clonal plasma cells proliferative disorder and is almost always preceded by an asymptomatic premalignant stage termed monoclonal Gammopathy of Undetermined Significance (MGUS). Diagnosis of myeloma is based on International Myeloma Working Group (IMWG) 2003 which requires one or more CRAB features including hypercalcemia, renal insufficiency, anemia and lytic bone lesions. The IMWG 2014 updated criteria for the diagnosis of myeloma allows the use of early indicators for therapy before CRAB features happen. This is a case of a 53-year-old male, based on complete blood count and peripheral blood smear having normochromic normocytic anemia, NRBC 7/100 leucocytes, thrombocytopenia, 1% plasmoblasts, 11% plasmocytes and Erythrocyte Sedimentation Rate (ESR) 40 mm. The bone marrow evaluation showed plasmocytes 22.5% ANC with abnormal morphology. The diagnosis myeloma was made based on IMWG 2014 by the presence of plasmocytes 22.5% ANC the bone marrow and having one of Myeloma Defining Events (MDEs) in the form of anemia with hemoglobin level 8.5 g/dL. In addition, patient did examinations of protein electrophoresis, immunofixation and ratio involved/uninvolved Free Light Chain (FLC) serum. The results of those examination confirmed the diagnosis that has been made based on IMWG 2014. Prognosis of the patient is poor by the presence of 11% plasmocytes on blood peripheral and ratio FLC kappa/lambda 0.0010.

 

Downloads

Download data is not yet available.

References

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Onc. 2014; 15: 538-48

Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011; 364(11): 1046-60.

Moreau P, Miguel JS, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 21(5): 1-5

Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2013; 88(3): 226-35

Rajkumar SV. New criteria for the diagnosis of multiple myeloma, and related disorders [Cited 2015 Aug 2]. Available from : http://www.myelomabeacon.com/news/2014/10/26/new-multiple-myeloma.

International Myeloma Foundation. Concise review of the disease, and treatment options [Cited 2015 Jul 25]. Available from : http://www. myeloma.org.

Al-Farsi K. Multiple Myeloma: An Update. OMJ. 2013; 28(1): 3-11

Downloads

Submitted

2018-09-30

Accepted

2018-09-30

Published

2018-09-30

How to Cite

[1]
Febrianthi, M. and Wirawan, R. 2018. DIAGNOSIS OF MYELOMA BASED ON THE 2014 INTERNATIONAL MYELOMA WORKING GROUP. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY. 24, 2 (Sep. 2018), 196–200. DOI:https://doi.org/10.24293/ijcpml.v24i2.1324.

Issue

Section

Case Report